Organon (OGN) is receiving significant investor attention. The pharmaceutical company shows declining earnings estimates for the current fiscal year (-7.9%) but modest growth expected for next year (+7%). Revenue growth remains flat to slightly negative. With a Zacks Rank #3 (Hold) rating and a Grade A valuation score indicating the stock trades at a discount to peers, the company is expected to perform in line with the broader market in the near term.

Organon (OGN), a pharmaceutical company, is being closely watched by investors. The stock has underperformed the S&P 500 over the past month (-0.4% vs +0.6%). Earnings estimates remain unchanged with expected EPS of $0.91 for the current quarter (down 9.9% YoY) and $3.37 for the fiscal year (down 7.9% YoY). Revenue is expected to decline slightly. The company received a Zacks Rank #3 (Hold) rating, suggesting it may perform in line with the broader market. However, it is trading at a discount to peers based on valuation metrics.

Brodsky & Smith law firm has announced investigations into multiple merger transactions, including Apogee Therapeutics (acquired by AbbVie for $135.11/share), Roku (acquired by Fox for $160/share), TruBridge (acquired by Inventurus for $26.25/share), and Organon (acquired by Sun Pharmaceutical for $14/share). The investigations focus on whether the respective boards breached fiduciary duties by failing to conduct fair processes and whether deal consideration provides fair value to shareholders.

Investor rights law firm Halper Sadeh LLC is investigating four companies for potential securities law violations and breaches of fiduciary duties related to their proposed acquisitions. The firm is examining whether shareholders are receiving fair consideration and whether insider benefits may be limiting superior competing offers.

Brodsky & Smith law firm is investigating four merger transactions to determine whether company boards breached fiduciary duties by failing to conduct fair processes and provide fair value to shareholders. The investigations involve Simulations Plus ($18.50/share), Roku ($160.00/share), TruBridge ($26.25/share), and Organon ($14.00/share).

Investor rights law firm Halper Sadeh LLC is investigating four major corporate transactions for potential securities law violations and breaches of fiduciary duties. The investigations cover Nuvalent's $124/share sale to GSK, SUNation Energy's merger with Suniva, Organon's $14/share sale to Sun Pharmaceutical, and Taylor Morrison's $72.50/share sale to Berkshire Hathaway. The firm is seeking increased consideration and additional disclosures on behalf of shareholders.

Hanmi Pharmaceutical has signed a supply agreement with Organon to export three combination medicines in cardiovascular and respiratory therapeutic areas to Malaysia and the Philippines. Organon will handle marketing, distribution, and sales in these markets, with potential for expansion in the medium to long term.

Hanmi Pharmaceutical has signed a supply agreement with Organon to export three combination medicines for cardiovascular and respiratory therapeutic areas to Malaysia and the Philippines. Organon will handle marketing, distribution, and sales in these markets, with potential for medium to long-term expansion. The partnership leverages the growing demand for combination therapies in Southeast Asia's rapidly expanding pharmaceutical market.

Brodsky & Smith law firm announced investigations into four merger transactions, examining whether company boards breached fiduciary duties by failing to conduct fair processes and pay fair value to shareholders. The investigations involve Veris Residential ($19.00/share), XOMA Royalty ($39.00/share), Organon ($14.00/share), and RE/MAX Holdings ($13.80/share or stock election).

Halper Sadeh LLC, an investor rights law firm, is investigating four companies for potential securities law violations and breaches of fiduciary duties related to proposed mergers and acquisitions. The firm is examining whether shareholders are receiving fair consideration and whether insider benefits may be prioritized over ordinary shareholder interests.

Investor rights law firm Halper Sadeh LLC is investigating four major companies for potential securities law violations and breaches of fiduciary duties. The investigations concern McCormick & Company's merger with Unilever's Foods business, Leggett & Platt's sale to Somnigroup International, Organon & Co.'s sale to Sun Pharmaceutical, and Kennedy-Wilson Holdings' sale to a consortium led by its CEO. The firm is seeking increased consideration and additional disclosures on behalf of shareholders.

Sirius XM is in preliminary discussions to acquire iHeartMedia in a potential merger of America's largest satellite radio provider and radio station owner. Other major deals include Eli Lilly acquiring AI startup Profluent for up to $2.25 billion, Sun Pharmaceutical acquiring Organon for $11.75 billion, and Uber purchasing Hong Kong-based FlyTaxi. Meanwhile, several companies filed for bankruptcy including Wren Kitchens, FreshRealm, and Smokey Bones BBQ.